Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis

OBJECTIVE: The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver-related events. However, whether there is a difference between the two agents in the extent of improving such outcom...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gut
Autori principali: Lee, Sung Won, Kwon, Jung Hyun, Lee, Hae Lim, Yoo, Sun Hong, Nam, Hee Chul, Sung, Pil Soo, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew, Han, Nam Ik, Jang, Jeong Won
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Hepatology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306978/
https://ncbi.nlm.nih.gov/pubmed/31672838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2019-318947
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi